Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, David Carbone, MD, PhD, of Ohio State University, Athens, OH, discusses the KEYNOTE-042 trial (NCT02220894), which compared pembrolizumab with chemotherapy for lung cancer. The results were positive in favor of pembrolizumab, and potentially practice-changing, as they represent a previously unmet need for treating certain lung cancer patient groups.
KEYNOTE-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy
